Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07477457 · ClinicalTrials.gov registry record · Phase 2
A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma
A Phase 2 study of Osteosarcoma and Metastasis, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 7
- Study locations
NCT07477457 is a Phase 2 study of Osteosarcoma and Metastasis that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 45 participants, below the 301-participant average among 46 other Osteosarcoma trials with a reported enrollment target (85% lower). The trial reports 7 study locations across 2 states.
The verdict
NCT07477457, a Phase 2 study of Osteosarcoma and Metastasis, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 7
- Study locations
Study Summary
The researchers are doing this study to find out whether adding gefitinib, trametinib, disulfiram, and sunitinib to standard chemotherapy is a more effective treatment approach for people with osteosarcoma than standard chemotherapy on its own. The researchers will also look at the safety of adding these drugs to standard chemotherapy. The researchers will also use the additional research biopsies from Cohort 1 participants to learn more about how osteosarcoma survives during chemotherapy.
Conditions Studied
Interventions
- DRUG Cisplatin
- DRUG Doxorubicin
- DRUG Trametinib
- DRUG Methotrexate
- DRUG Gefitinib
Study Locations (7)
New York
- Memorial Sloan Kettering at Suffolk-Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering at Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activites) - New York
- Memorial Sloan Kettering at Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering at Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering at Bergen (Limited Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2026-03-11 |
| Est. Completion | 2028-03-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07477457
The ClinicalTrials.gov registry entry for NCT07477457 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 301-participant average among 46 other Osteosarcoma trials with a reported enrollment target (85% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Osteosarcoma appearing as the primary indexed condition, and to 5 interventions - of which Cisplatin is the first listed.
NCT07477457 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT07477457 about?
NCT07477457 is a clinical study titled "A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma". The researchers are doing this study to find out whether adding gefitinib, trametinib, disulfiram, and sunitinib to standard chemotherapy is a more effective treatment approach for people with osteosarcoma than standard chemotherapy on its own. The researchers will also look at the safety of adding ...
What is the current status of trial NCT07477457?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2026-03-11. Estimated completion is 2028-03-11.
What conditions does trial NCT07477457 study?
This clinical trial studies the following conditions: Osteosarcoma, Metastasis.
What interventions are being tested in trial NCT07477457?
The interventions under investigation include: Cisplatin (DRUG), Doxorubicin (DRUG), Trametinib (DRUG), Methotrexate (DRUG), Gefitinib (DRUG).
Who is sponsoring clinical trial NCT07477457?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07477457 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
RECRUITING · Phase 2
-
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
ACTIVE NOT RECRUITING · Phase 2
-
Olaparib With Ceralasertib in Recurrent Osteosarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma
ACTIVE NOT RECRUITING · Phase 2
-
SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.